TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06475001
Drug: VER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil.
Study: NCT06475001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator without active ingredient
Study: NCT06499025
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion
Study: NCT05178550
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous \[iv\] injection
Study: NCT06070701
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.
Study: NCT05944978
Drug: GNC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
Study: NCT04229758
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
Study: NCT06306014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period
Study: NCT06299826
Drug: AZD5462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.
Study: NCT04999592
Drug: Standard of care without prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer antibiotics in response to infection
Study: NCT06299826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching doses of film-coated tablets of Placebo OD orally.
Study: NCT06679036
Drug: Fluvustat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvustat
Study: NCT04999592
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 gm IV q12h for 3 days
Study: NCT06460298
Drug: ProAgio Dose Levels (DL) 1,2,3,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
Study: NCT05232370
Drug: Angiotensin converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors after Kidney Transplant
Study: NCT04783935
Drug: Mavenclad®
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Study: NCT05014061
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion 70 µg/kg/min for 6 hours
Study: NCT05137262
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05137262
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06698263
Drug: Control group (placebo)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administration
Study: NCT05712746
Drug: Samtasu for I.V. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.
Study: NCT06653400
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: 2 mL (30 mg) of ketorolac
Study: NCT06102863
Drug: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Study: NCT06699771
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT06604949
Drug: LP-003 200mg
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 200 mg LP-003
Study: NCT06604949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo
Study: NCT05594615
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive rosuvastatin once daily on Days 2 and 13
Study: NCT05594615
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive caffeine once daily on Days 1 and 12
Study: NCT05526924
Drug: Fluorouracil (5FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A chemotherapy drug used to treat different types of cancer.
Study: NCT05446376
Drug: 68Ga-citrate PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Study: NCT06393673
Drug: HS-10384 tablet Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD
Study: NCT04527549
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04287543
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
Study: NCT04287543
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
Study: NCT04745260
Drug: Intranasal Fentanyl Spray and Intranasal Midazolam Spray
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
Study: NCT06427083
Drug: Envlo Tablet
Normalized name: ENVIO 30 Day Daily Essentials Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enavogliflozin 0.3mg
Study: NCT06427083
Drug: Envolomet SR Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enavogliflozin 0.3mg/Metformin1,000mg
Study: NCT04419389
Drug: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
Study: NCT06220201
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05968482
Drug: Diclofenac Sodium Gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical application on both knees
Study: NCT05667701
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo also administered twice daily.
Study: NCT06625190
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion.
Study: NCT05277480
Drug: Apatinib+IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
Study: NCT05277480
Drug: IE
Normalized name: KIE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ifosfamide ivgtt ; etoposide ivgtt .
Study: NCT05153226
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
Study: NCT06385262
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
Study: NCT06396091
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
Study: NCT04532489
Drug: FNP-59
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Study: NCT05330884
Drug: Oral Chemoprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
Study: NCT05537740
Drug: BAY3375968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06272227
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
Study: NCT05987423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection
Study: NCT05115955
Drug: DS group
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
Study: NCT05115955
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
Study: NCT05143905
Drug: AZD7503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
Study: NCT05143905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive placebo by SC injection
Study: NCT04695613
Drug: Aminoacid
Normalized name: Acid-aminoacid ligase
Approvals — FDA: no, EMA: no, PMDA: no
Description: amino acid infusion 150 ml/kg/hr starting preoperative
Study: NCT05622162
Drug: Radiopharmaceutical 18F-Fluorocholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study.
Study: NCT04976270
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3667 capsules
Study: NCT06277466
Drug: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Study: NCT04976270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT05910450
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
Study: NCT06280794
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
Study: NCT05580588
Drug: SPH4336
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SPH4336 PO QD
Study: NCT05744219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04514302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
Study: NCT05974267
Drug: M5717 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
Study: NCT05227690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study: NCT04646564
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Study: NCT06593366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
Study: NCT06623526
Drug: YHR2402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug: YHR2402
Study: NCT06623526
Drug: YHR2402+YHR2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug: YHR2402+YHR2403
Study: NCT05019638
Drug: Regional anesthesia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% with epinephrine 1:400,000.
Study: NCT05019638
Drug: Local multimodal analgesia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
Study: NCT06446401
Drug: ADT + NHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.
Study: NCT05684796
Drug: Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
Study: NCT06434597
Drug: SPH5030
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH5030：Oral, QD, 600mg
Study: NCT05362955
Drug: Intravaginal 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
Study: NCT05462613
Drug: FOLFIRI or FOLFOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 2 weeks according to investigator practice
Study: NCT03941132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.
Study: NCT06582888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT05303727
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day for 2 days in cord blood stem cell transplantation
Study: NCT05303727
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
Study: NCT06074705
Drug: DS-1471a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration on Day 1 of each 28-day cycle
Study: NCT06126822
Drug: Zabdeno® booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single Zabdeno® booster vaccination
Study: NCT06126822
Drug: Ervebo® booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single Ervebo® booster vaccination
Study: NCT05509153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
Study: NCT06477406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An active placebo containing supplemental terpenes matched to the high-CBD product.
Study: NCT04941443
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
Study: NCT05247528
Drug: MANP
Normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel designer peptide to represent a pGC-A/cGMP therapeutic
Study: NCT05247528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05638919
Drug: Oral Antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nirmatrelvir plus ritonavir or molnupiravir
Study: NCT05729373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily tablet
Study: NCT06449937
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.
Study: NCT05402371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo soft gel capsule
Study: NCT05973149
Drug: QLH12016
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to the scheme description
Study: NCT06483555
Drug: NALIRIFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
Study: NCT06483555
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
Study: NCT06703268
Drug: HSK7653 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 10 mg Q2W
Study: NCT06703268
Drug: Daily DPP-4 inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily DPP-4 inhibitor
Study: NCT04951167
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in the form of infusion
Study: NCT04951167
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in the form of bolus
Study: NCT04772742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - solution for infusion
Study: NCT06637865
Drug: IMP761
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT06637865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT06096259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
Study: NCT06793397
Drug: CYB003
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYB003 is a synthetic psilocybin analog.
Study: NCT05330078
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
Study: NCT06795503
Drug: Docetaxel plus cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.
Study: NCT06079801
Drug: anti-CGRP-mAbs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies